Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England
暂无分享,去创建一个
K. Khunti | F. Zaccardi | J. Morgan | V. Nafilyan | Isobel L. Ward | A. Banerjee | C. Bermingham | J. Stanborough | J. Doidge | I. Ward
[1] Colin Simpson,et al. Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland , 2022, Nature Communications.
[2] L. Hartling,et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review , 2022, BMJ.
[3] M. Gulliford,et al. Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK , 2022, PLoS medicine.
[4] S. Brunak,et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors , 2022, Nature Communications.
[5] S. Gharbia,et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.
[6] Paul J. Birrell,et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines , 2022, Nature Medicine.
[7] M. Bertrand,et al. A modified self‐controlled case series method for event‐dependent exposures and high event‐related mortality, with application to COVID‐19 vaccine safety , 2022, Statistics in medicine.
[8] Michael John Smith,et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. , 2022, JAMA.
[9] K. Khunti,et al. Risk of myocarditis following sequential COVID-19 vaccinations by age and sex , 2021, medRxiv.
[10] H. Sørensen,et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study , 2021, BMJ.
[11] R. Viner,et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year , 2021, Nature Medicine.
[12] K. Khunti,et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection , 2021, Nature Medicine.
[13] A. Gundlapalli,et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[14] P. Farrington,et al. Avoiding bias in self‐controlled case series studies of coronavirus disease 2019 , 2021, Statistics in medicine.
[15] K. Khunti,et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study , 2021, BMJ.
[16] P. Farrington,et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study , 2021, The Lancet.
[17] C. Robertson,et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study , 2021, BMJ.
[18] D. Swerdlow,et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.
[19] David A. Drew,et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study , 2021, The Lancet Infectious Diseases.
[20] Heather J. Whitaker,et al. Self-controlled case series studies : a modelling guide with R , 2018 .
[21] Irene Petersen,et al. Self controlled case series methods: an alternative to standard epidemiological study designs , 2016, British Medical Journal.
[22] O. Wichmann,et al. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review , 2015, BMC Infectious Diseases.
[23] K. Wilson,et al. Drug safety studies and measures of effect using the self‐controlled case series design , 2013, Pharmacoepidemiology and drug safety.
[24] Heather J Whitaker,et al. Case series analysis for censored, perturbed, or curtailed post-event exposures. , 2008, Biostatistics.
[25] Patrick Musonda,et al. Tutorial in biostatistics: the self‐controlled case series method , 2006, Statistics in medicine.